FT : The reunion of BP and Transocean is sending a signal to the oil market

The reunion of BP and Transocean is sending a signal to the oil market
Tight market for oil rigs might restrain supply even if producers pull back from projects

There is a feeling of déjà vu about BP’s big new oil project. Not just because the company is returning to the Gulf of Mexico, 15 years after the Deepwater Horizon accident killed 11 people, spilled 5mn barrels of oil and cost the company more than $60bn. 

It is also because it is drilling its new Kaskida field, where oil sits about six miles below the surface of the sea at an incredibly high pressure, with the same company that owned Deepwater Horizon: Transocean.

This time around, the drillship is called the Deepwater Atlas. Before you raise your eyebrows at the reunion, BP had little choice; Transocean was the only company with an available drillship capable of handling the high pressure of the oil reservoir.

Indeed BP was forced to pay a high price, roughly $635,000 a day, to secure the Deepwater Atlas, since Transocean’s fleet is almost fully booked. Its chief executive said last month that its rigs are 97 per cent booked for next year and 86 per cent for the first half of 2026. He boasted that the company had a backlog of work worth $9.3bn. 

Since the start of 2022, the average day rate for floating oil rigs has risen by more than 40 per cent according to analysts tracking the industry at Rystad, an energy consultancy. Since renting a rig accounts for between 20 per cent and 40 per cent of the cost of developing an oilfield, the rise in prices, combined with rig availability, has implications for how much oil is going to come on to the market over the next few years.

The number of future rig contracts is already falling as companies, fretting over a possible oversupply of oil, exercise restraint in starting new projects. The worries have seen the share prices of some leading rig operators fall nearly 30 per cent in the last year, despite the current boom.

The story of the Deepwater Atlas illustrates the boom and bust of the market. The ship was commissioned from a yard in Singapore in 2014, back when the price of oil was more than $115 a barrel and companies were falling over themselves to find and develop more offshore oil. But almost as soon as work started on the $1bn vessel, the oil market collapsed as Saudi Arabia fought a price war against oil from the US shale patch and Russia.


Contractors quickly learnt how vicious the cycle can be; plenty of oil companies simply walked away from their contracts. How much oil the world would need in the future was increasingly unclear as oil companies diverted some spending to low-carbon projects and the Covid-19 pandemic hit demand and introduced the idea that gas-guzzling commuters might prefer to work from home. Transocean put the Deepwater Atlas deal on ice for years, only taking delivery in 2022.

The supply-demand balance now looks better for the oil rig companies. There has been significant consolidation in the offshore supply chain, plenty of older rigs have been scrapped and few companies are brave enough to place new orders.

And offshore oil is back, particularly in the US, Brazil and Guyana, but also in Africa and Asia. This year, oil companies will spend more than $100bn on offshore projects, rising to nearly $140bn in 2027, according to Rystad. With more deepwater oil being extracted, some analysts are now even expecting a glut of oil to hit the market in the next few years. By the end of the decade, the International Energy Agency thinks there may be as much as 8mn barrels a day of spare capacity, an amount never seen outside of the Covid pandemic.

Much depends on how quickly the demand for oil fades, especially in China, where consumers are switching rapidly to electric cars. But the tightness of the rig market may also point to constraints on supply. Offshore projects take years to develop and often over a decade to break even. If oil prices wane, they get put on ice while oil companies focus on cheaper and easier prospects.

Since April, despite wars in Europe and the Middle East, the price of crude has fallen more than 15 per cent, as traders fret over the Chinese economy. Rystad believes that three-quarters of the offshore projects looked at by oil majors will be approved at a $60 price for crude. Rig owners are also bullish. Transocean says some of its customers have boasted they can make a 20 per cent return even at $40 oil. 

But for rig operators to invest in new capacity, and to brave their shareholders’ reticence about capital spending, it will take several years of stable oil prices, as well as an expectation that the world’s oil needs can only be met from offshore drilling. That still looks like a tough call at the moment.

FT : UK air taxi company Vertical Aerospace wins $50mn lifeline from creditor

UK air taxi company Vertical Aerospace wins $50mn lifeline from creditor
Founder loses control to US distressed debt investor Mudrick Capital with debt to equity swap

UK entrepreneur Stephen Fitzpatrick will cede control of Vertical Aerospace, the air taxi start-up he founded, as part of a rescue deal with its largest creditor, ending a protracted fight for the future of the company.

Vertical said on Monday it had secured up to $50mn in new funding from Mudrick Capital, a US distressed debt investor, staving off a cash crunch at the Bristol-based company, which employs about 300 people.

As part of the agreement, about $130mn of loans from Mudrick Capital — half of the outstanding amount — will be converted into equity at $2.75 a share, reducing Vertical’s debt. The repayment date for the balance will be extended to December 2028.

The deal will make Mudrick Capital, founded by Jason Mudrick in 2009, the largest shareholder in Vertical with a stake of just over 70 per cent. Fitzpatrick’s stake will fall from 70 to around 20 per cent and he will remain on the board as a non-executive director. Vertical will continue to operate from the UK. 

Stuart Simpson, chief executive of Vertical, said the deal, which has been under discussion for months, would strengthen Vertical’s balance sheet and pave the way for a fresh fundraising round.

As part of the commitment, Mudrick will invest $25mn upfront and backstop another $25mn that will be reduced by any amounts raised from third parties. Fitzpatrick reserves the option to invest a further $25mn. 

Simpson said the most important part of the agreement was “deleveraging the balance sheet”, adding that the convertible loan notes had been an “impediment to raising equity”.

The future of Vertical, which is listed on the New York Stock Exchange, has been in the balance for months as its cash reserves dwindled to $60mn at the end of September. Its shares closed at $4.79 on Friday.

Simpson said the new funding would give Vertical enough “runway through to the end of 2025”.

Mudrick said the agreement “underscores our appreciation of Vertical Aerospace’s position in the [electric vertical take-off and landing] sector”. 

Fitzpatrick, who is best known in the UK for founding Ovo Energy, welcomed the deal. He set up Vertical in 2015 after becoming convinced of the merits of air taxis while stuck in a traffic jam in São Paulo. 

The company is one of a number of flying-taxi companies that went public as special purpose vehicles in 2021, attracting billions of dollars of investment. Most, however, have struggled with high development costs and regulatory approval. German start-up Lilium, which was also listed on the NYSE, filed for insolvency this month. 

Vertical has been testing its VX4 vehicle, which will have a range of up to 100 miles, a cruise speed of 150mph and capacity for four passengers. Simpson said the company was committed to bringing its air taxi to market in 2028, describing the timeline as “realistic”.

FT : Natixis in talks with Generali over asset management tie-up

Natixis in talks with Generali over asset management tie-up
Deal would bring together two of the biggest names in European asset management

France’s Natixis Investment Managers, which has $1.3tn in assets under management, is in early-stage talks with Italian insurer Generali about a potential tie-up, according to several people familiar with the situation. 

Such a combination would bring together two of the biggest names in European asset management as the sector turns to dealmaking to scale up and expand distribution.

Terms are not agreed and it is not certain that the talks between Natixis and Generali will lead to a deal, the people said. Natixis was not immediately available to comment. Generali and Groupe BPCE, the majority owner of Natixis, declined to comment.

>>> Europe : Brokers Upgrades & Downgrades - 25th of November 2024 V3(++)

>>> Up
* 3i Raised to Overweight at Morgan Stanley; PT 4,069 pence
* Alfa Laval Raised to Buy at Deutsche Bank (+)
* Aroundtown Raised to Hold at Deutsche Bank (+)
* Bachem Raised to Buy at Octavian; PT 86 Swiss francs
* Banco BPM Raised to Outperform at Mediobanca SpA; PT 8.20 euros
* Barratt Redrow PLC Raised to Buy at Jefferies; PT 507 pence
* Cava Group PT Raised to $158 from $128 at Argus (++)
* Coinbase PT Raised to $358 from $265 at Oppenheimer (++)
* CrowdStrike PT Raised to $400 from $325 at Evercore ISI (+)
* Equinor Raised to Overweight at Barclays; PT 400 kroner
* Elastic Raised to Outperform at Wedbush; PT $135
* JD Sports Raised to Hold at Deutsche Bank (+)
* Liontrust Raised to Buy at Peel Hunt; PT 560 pence
* LWB PW Raised to Neutral-Short Term Sell at Santander Biuro Maklerskie (+)
* MicroStrategy PT Raised to $510 from $300 at Canaccord (+)
* Nordea Bank Raised to Overweight at Morgan Stanley
* Reddit PT Raised to $175 from $120 at Jefferies (+)
* Robinhood Raised to Overweight at Morgan Stanley; PT $55
* Santander Raised to Overweight at Morgan Stanley; PT 5.90 euros
* Santander Brasil ADRs Raised to Overweight at JPMorgan; PT $6
* Siemens Energy PT Raised to 70 euros from 35 euros at Berenberg
* Snowflake Raised to Outperform at Wedbush; PT $190
* Vestas Raised to Buy at Deutsche Bank (+)
* Walmart PT Raised to $100 from $80 at Argus (++)
* Weir Group PLC/The Raised to Buy at Deutsche Bank (+)

>>> Down
* Barrick Gold Cut to Neutral at CIBC; PT C$30.75
* Beneteau Cut to Neutral at CIC; PT 8 euros (+
* CaixaBank Cut to Equal-Weight at Morgan Stanley; PT 6.25 euros
* Dassault Aviation Cut to Hold at Kepler Cheuvreux
* Hiscox PT Cut to 1,000 pence from 1,150 pence at Jefferies
* ING Cut to Equal-Weight at Morgan Stanley; PT 17.50 euros
* Kone Cut to Underperform at RBC; PT 44 euros
* Orsted Cut to Neutral at Goldman; PT 445 kroner
* Seri Industrial Cut to Neutral at Intermonte; PT 3.50 euros (++)
* Thales Cut to Hold at Kepler Cheuvreux
* VGP Cut to Hold at Deutsche Bank (+)

>>> Initiation
* Canatu Rated New Buy at Bryan Garnier; PT 15 euros (+)
* Lundbergforetagen Rated New Sell at ABG; PT 493 kronor

>>> Call
* 3i Raised at Morgan Stanley, CVC Now Top Diversified Pick
* Kone Cut to Underperform at RBC on Downside Risks to Consensus
* Morgan Stanley Strategists Say Europe Financials Lead EPS Beats (+)
* Nordea, Santander Raised at Morgan Stanley, Now Among Top Picks
* RBC’s Calvasina Sees S&P 500 Rallying 11% Through End of 2025 (+)
* Mega Cap Outperformance Not Due to Passive Flows: Citigroup (+)

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Banco Santander Brasil (BSBR) upgraded to Overweight from Neutral at JP Morgan; tgt lowered to $6
    • Elastic (ESTC) upgraded to Outperform from Neutral at Wedbush; tgt $135
    • Equinor (EQNR) upgraded to Overweight from Equal Weight at Barclays
    • Jones Lang LaSalle (JLL) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $353
    • KinderCare Learning Companies (KLC) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt $30
    • Procter & Gamble (PG) upgraded to Buy from Neutral at DA Davidson; tgt raised to $209
    • Robinhood Markets (HOOD) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $55
    • Sally Beauty (SBH) upgraded to Buy from Hold at TD Cowen; tgt raised to $16
    • Snowflake (SNOW) upgraded to Outperform from Neutral at Wedbush; tgt $190
    • Synchronoss Tech (SNCR) upgraded to Buy from Neutral at ROTH MKM; tgt raised to $13
    • The Trade Desk (TTD) upgraded to Neutral from Sell at New Street; tgt raised to $115
    • U.S. Bancorp (USB) upgraded to Buy from Neutral at Citigroup; tgt raised to $65
    • W.R. Berkley (WRB) upgraded to Buy from Neutral at Goldman; tgt $69
  • Downgrades:
    • Arthur J. Gallagher (AJG) downgraded to Neutral from Buy at Goldman; tgt $313
    • Banco Bradesco (BBD) downgraded to Neutral from Overweight at JP Morgan
    • Block (SQ) downgraded to Market Perform from Outperform at BMO Capital Markets; tgt raised to $100
    • Community Health (CYH) downgraded to Underweight from Equal Weight at Wells Fargo; tgt lowered to $2.50
    • Despegar.com (DESP) downgraded to Sell from Buy at TD Cowen; tgt raised to $14
    • Eagle Materials (EXP) downgraded to Hold from Buy at Loop Capital; tgt $315
    • Editas Medicine (EDIT) downgraded to Underperform from Buy at BofA Securities; tgt lowered to $1
    • Expensify (EXFY) downgraded to Mkt Perform from Mkt Outperform at JMP Securities
    • Five Below (FIVE) downgraded to Market Perform from Outperform at Telsey Advisory Group; tgt lowered to $95
    • HCA (HCA) downgraded to Underweight from Equal Weight at Wells Fargo; tgt lowered to $320
    • M&T Bank (MTB) downgraded to Neutral from Buy at Citigroup; tgt raised to $230
    • Mainz Biomed B.V. (MYNZ) downgraded to Neutral from Buy at H.C. Wainwright
    • Newmark Group (NMRK) downgraded to Peer Perform from Outperform at Wolfe Research
    • NIO (NIO) downgraded to Sell from Neutral at Goldman; tgt lowered to $3.90
    • Perspective Therapeutics (CATX) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $5
    • Red Rock Resorts (RRR) downgraded to Neutral from Outperform at Mizuho; tgt lowered to $44
    • Select Medical (SEM) downgraded to Hold from Buy at The Benchmark Company
    • Smith Douglas Homes Corp (SDHC) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $36
    • Tenet Healthcare (THC) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $150
  • Others:
    • AES (AES) resumed with an Underperform at BofA Securities; tgt $11
    • Apogee Therapeutics (APGE) initiated with a Buy at Canaccord Genuity; tgt $89
    • Arm Holdings plc (ARM) initiated with a Buy at UBS; tgt $160
    • Berry Global (BERY) resumed with an Overweight at JP Morgan; tgt raised to $76
    • Berry Global (BERY) resumed with a Neutral at Citigroup; tgt $76
    • Brown-Forman (BF.B) initiated with an Outperform at Exane BNP Paribas; tgt $48
    • Constellation Brands (STZ) initiated with a Neutral at Exane BNP Paribas; tgt $261
    • Coursera (COUR) initiated with a Neutral at JP Morgan; tgt $8
    • CSW Industrials (CSWI) initiated with an Equal Weight at Wells Fargo; tgt $425
    • Hannon Armstrong Sust. Infr. (HASI) resumed with a Buy at BofA Securities; tgt $40
    • Immunic (IMUX) initiated with a Buy at H.C. Wainwright; tgt $10
    • Manhattan Assoc (MANH) initiated with an Overweight at Piper Sandler; tgt $326
    • MARA Holdings Inc. (MARA) initiated with an Equal Weight at Barclays; tgt $27
    • Marsh McLennan (MMC) resumed with an Outperform at Evercore ISI; tgt $242
    • Molson Coors Brewing (TAP) initiated with a Neutral at Exane BNP Paribas; tgt $64
    • Sarepta Therapeutics (SRPT) initiated with a Sell at H.C. Wainwright; tgt $80
    • Shoals Technologies (SHLS) initiated with a Buy at BofA Securities; tgt $6
    • SPS Commerce (SPSC) initiated with a Neutral at Piper Sandler; tgt $198
    • SPX Technologies (SPXC) initiated with an Outperform at Wolfe Research; tgt $199
    • Viridian Therapeutics (VRDN) initiated with a Buy at TD Cowen
    • V2X (VVX) initiated with a Buy at BTIG Research; tgt $80

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • M -2.5% (Q3 revs above consensus, delays Q3 earnings report)
Other news:
  • BHVN -14.4% (Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity)
  • SAVA -5.4% (Topline Phase 3 Data Did Not Meet Co-Primary Endpoints)
  • REPL -3.9% (announces a proposed public offering of $125 mln of shares of its common stock and pre-funded warrants to purchase shares of common stock)
  • BTU -3.3% (to acquire Tier 1 Australian metallurgical coal assets from Anglo American)
  • CYH -2.5% (enters definitive agreement to sell ShorePoint Health System in Florida for $265 mln)
  • SUM -2.2% (Summit Materials Enters into definitive agreement to be acquired by Quikrete for $52.50/share in cash)
  • CPK -1.7% (establishes $100 mln at-the-market equity offering program)
  • LMT -1.3% (awarded a $870 mln US Navy contract)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • UXIN +15.5%, BBWI +13%
Other news:
  • NVX +22.8% (signs binding offtake agreement with PowerCo)
  • BBIO +19.2% (reports Attruby (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients)
  • EVTL +7.5% (receives $50 million in new funding as part of $180 million transaction that will strengthen its financial position and advance its Flightpath 2030 Strategy)
  • ORGO +5.7% (announces plans to expand its manufacturing capacity with new long-term lease for biomanufacturing facility in Rhode Island)
  • MSTR +5.2% (Barron's out positive on MSTR)
  • EQT +4.3% (confirms $3.5 billion midstream joint venture with Blackstone (BX) Credit & Insurance)
  • NTLA +4.1% (FDA has granted Regenerative Medicine Advanced Therapy designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy)
  • SMLR +2.9% (reports updated bitcoin and ATM activity; Company launches additional $50.0 mln ATM offering)
  • ENLC +2.8% (ONEOK agrees to acquire remaining publicly held common units in EnLink midstream in a tax-free transaction)
  • QSI +2.5% (announces organizational restructuring program, including workforce reduction)
  • ALNY +2.5% (announces that the U.S. FDA has accepted for review the Company's supplemental New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy)
  • ETON +2.3% (acquires U.S. rights to Amglidia)
  • POET +1.5% (announces its intention to expand its optical engine production capacity in Malaysia)
  • GMED +1.4% (announces commercial launch of ExcelsiusHub navigation system)
  • NNDM +1.4% (Leading Proxy Advisory Firm Glass Lewis Recommends Nano Dimension Shareholders Vote "FOR" Both of Murchinson's Independent Director Nominees)
  • TXNM +1.3% (files application for new resources in 2028)
  • CVE +1.2% (announces redemption of Series 3 Preferred Shares)
  • NU +1.2% (receives approval to consolidate its operations under a single company)

Le Monde : Le luxe a perdu 50 millions de clients en deux ans

Le luxe a perdu 50 millions de clients en deux ans
Le recul du marché des produits de luxe devrait atteindre 2 % en 2024, d’après une étude réalisée par le cabinet Bain & Company, en partenariat avec l’association italienne Altagamma.

LVMH devra revoir sa stratégie. Tout comme Kering, Burberry et autres Chanel. Le marché mondial du luxe essuiera un recul de 1 % à 3 % en 2024, pour atteindre 1 500 milliards d’euros, selon l’étude Bain & Company, réalisée en partenariat avec Altagamma, association italienne des fabricants de luxe, et publiée, jeudi 14 novembre.

Le segment des articles de maroquinerie, prêt-à-porter, joaillerie et horlogerie, qui représente environ un quart de ce montant, devrait être en repli de 2 % sur un an, à taux de change constant. Initialement, Bain & Company tablait sur un tout autre scénario, avec une croissance comprise entre 0 % et 4 %. Mais le retournement du marché chinois du luxe, ressenti depuis la fin du deuxième trimestre, a obligé le cabinet à revoir ses prévisions. « Pour la première fois depuis la grande récession de 2008, en dehors de la période Covid, le marché va essuyer un ralentissement », souligne, dans un communiqué, Claudia D’Arpizio, associée de Bain & Company.

Erreurs de stratégie
A Milan, capitale du luxe italien, le cabinet de conseil international pointe les erreurs de stratégie commises par certains grands fabricants de luxe pour faire face au ralentissement de la demande aux Etats-Unis et en Chine, et compenser la baisse des volumes de ventes. Plusieurs ont eu recours à la « premiumisation » des gammes ; en clair, les fabricants ont augmenté les prix de leurs produits. En début d’année, Hermès a ainsi appliqué une hausse de prix de l’ordre de 9 %. Mais cette stratégie n’a pas été payante pour les marques plus abordables, dont l’italien Gucci, filiale du groupe Kering, et Burberry, figure britannique du luxe.

« Cette tendance (…) a débouché sur un rétrécissement de la base de clientèle », déplore Bain & Company, en chiffrant à 50 millions le nombre de clients perdus depuis 2022. Les prix stratosphériques pratiqués par les marques de maroquinerie (3 000 euros pour un sac Dior en coton, plus de 5 000 euros pour un fourre-tout Hermès, etc.) auraient rebuté les représentants de la génération Z, c’est-à-dire les moins de 35 ans, qu’elles étaient parvenues à conquérir, en particulier en Chine. Confrontés au chômage, ces derniers sont désormais plus économes. D’après une étude de Bain & Company, 40 % des clients du secteur du luxe jugent les prix pratiqués trop élevés. « Il est temps que les marques revoient leurs propositions », note Mme D’Arpizio.

Parmi les pistes de relance du secteur figure aussi la conquête de nouveaux territoires, en Amérique latine, en Inde, en Asie du Sud-Est et au Moyen-Orient, selon le cabinet de conseil. Les classes moyennes-supérieures susceptibles d’acheter des produits de luxe devraient y croître de « 50 millions de personnes d’ici à 2030 », calcule-t-il. D’ici là, grâce au « déploiement de politiques macroéconomiques », Bain & Company estime que le marché du luxe devrait bénéficier d’un contexte « légèrement plus favorable en 2025 ».